Page 72 - Read Online

de Kouchkovsky et al. J Transl Genet Genom 2021;5:265-77 https://dx.doi.org/10.20517/jtgg.2021.32 Page 277

carcinomas. Epigenetics 2016;11:184-93. DOI PubMed PMC
57. Zhao SG, Chen WS, Li H, et al. The DNA methylation landscape of advanced prostate cancer. Nat Genet 2020;52:778-89. DOI
PubMed PMC
58. Choi SYC, Ettinger SL, Lin D, et al. Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine
prostate cancer. Cancer Med 2018;7:3385-92. DOI PubMed PMC
59. Li W, Cohen A, Sun Y, et al. The role of CD44 in glucose metabolism in prostatic small cell neuroendocrine carcinoma. Mol Cancer
Res 2016;14:344-53. DOI PubMed PMC
60. Reina-Campos M, Linares JF, Duran A, et al. Increased serine and one-carbon pathway metabolism by PKCλ/ι deficiency promotes
neuroendocrine prostate cancer. Cancer Cell 2019;35:385-400.e9. DOI PubMed PMC
61. Clermont PL, Lin D, Crea F, et al. Polycomb-mediated silencing in neuroendocrine prostate cancer. Clin Epigenetics 2015;7:40. DOI
PubMed PMC
62. Puca L, Bareja R, Prandi D, et al. Patient derived organoids to model rare prostate cancer phenotypes. Nat Commun 2018;9:2404. DOI
PubMed PMC
63. Shan J, Al-Muftah MA, Al-Kowari MK, et al. Targeting Wnt/EZH2/microRNA-708 signaling pathway inhibits neuroendocrine
differentiation in prostate cancer. Cell Death Discov 2019;5:139. DOI PubMed PMC
64. Zhang Y, Zheng D, Zhou T, et al. Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-
EZH2-TSP1 pathway in prostate cancers. Nat Commun 2018;9:4080. DOI PubMed PMC
65. Li Y, Donmez N, Sahinalp C, et al. SRRM4 drives neuroendocrine transdifferentiation of prostate adenocarcinoma under androgen
receptor pathway inhibition. Eur Urol 2017;71:68-78. DOI PubMed
66. Cavadas MA, Mesnieres M, Crifo B, et al. REST is a hypoxia-responsive transcriptional repressor. Sci Rep 2016;6:31355. DOI
PubMed PMC
67. Lapuk AV, Wu C, Wyatt AW, et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype
in prostate cancer. J Pathol 2012;227:286-97. DOI PubMed PMC
68. Chang YT, Lin TP, Campbell M, et al. REST is a crucial regulator for acquiring EMT-like and stemness phenotypes in hormone-
refractory prostate cancer. Sci Rep 2017;7:42795. DOI PubMed PMC
69. Jia L, Berman BP, Jariwala U, et al. Genomic androgen receptor-occupied regions with different functions, defined by histone
acetylation, coregulators and transcriptional capacity. PLoS One 2008;3:e3645. DOI PubMed PMC
70. Cai C, He HH, Chen S, et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor
through recruitment of lysine-specific demethylase 1. Cancer Cell 2011;20:457-71. DOI PubMed PMC
71. Liang Y, Ahmed M, Guo H, et al. LSD1-mediated epigenetic reprogramming drives CENPE expression and prostate cancer
progression. Cancer Res 2017;77:5479-90. DOI PubMed
72. Hino S, Kohrogi K, Nakao M. Histone demethylase LSD1 controls the phenotypic plasticity of cancer cells. Cancer Sci
2016;107:1187-92. DOI PubMed PMC
73. Coleman DJ, Sampson DA, Sehrawat A, et al. Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by
SRRM4. Neoplasia 2020;22:253-62. DOI PubMed PMC
74. Alumkal JJ, Sun D, Lu E, et al. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated
with enzalutamide resistance. Proc Natl Acad Sci U S A 2020;117:12315-23. DOI PubMed PMC
75. Zhang D, Park D, Zhong Y, et al. Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate
cancer. Nat Commun 2016;7:10798. DOI PubMed PMC
76. Beltran H, Oromendia C, Danila DC, et al. A phase II trial of the Aurora Kinase A inhibitor alisertib for patients with castration-
resistant and neuroendocrine prostate cancer: efficacy and biomarkers. Clin Cancer Res 2019;25:43-51. DOI PubMed PMC
77. Liu B, Li L, Yang G, et al. PARP inhibition suppresses GR-MYCN-CDK5-RB1-E2F1 signaling and neuroendocrine differentiation in
castration-resistant prostate cancer. Clin Cancer Res 2019;25:6839-51. DOI PubMed PMC
78. Aggarwal RR, Schweizer MT, Nanus DM, et al. A phase Ib/IIa study of the pan-BET inhibitor ZEN-3694 in combination with
enzalutamide in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2020;26:5338-47. DOI PubMed PMC
79. Knutson SK, Wigle TJ, Warholic NM, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma
cells. Nat Chem Biol 2012;8:890-6. DOI PubMed
80. McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature
2012;492:108-12. DOI PubMed